Drug Trial Radar · NCT01271985
Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill
Last checked: Nov 19, 2026Latest source record: Jan 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,410
Actual
Start
Feb 2011
Primary completion
Jan 2019
Study completion Jan 2019
Sponsor
- Lead sponsor
- Tehran University of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Golestan University of Medical sciences; University of Birmingham
- First posted
- Jan 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effects of PolyPill tablet (a fixed dose combination of two anti-hypertensive medications, atorvastatin and aspirin) on primary and secondary prevention of cardiovascular disease in Iranian adults older than 50.
Conditions
- Cardiovascular Diseases
Interventions
PolyPillDrug
A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
Minimal careOther
Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first major cardiovascular eventTime frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Golestan Cohort Study Center
Gonbad, Golestan Province, Iran
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.